Literature DB >> 11286732

TB vaccines: progress and problems.

P Andersen1.   

Abstract

Tuberculosis (TB) is the biggest killer worldwide of any infectious disease, a situation worsened by the advent of the HIV epidemic and the emergence of multi-drug resistant strains of Mycobacterium tuberculosis. The existing vaccine, Mycobacterium bovis bacille Calmette-Guérin (BCG), has proven inefficient in several recent field trials. There is currently intense research using cutting-edge vaccine technology to combat this ancient disease. However, it is necessary to understand why BCG has failed before we can rationally develop the next generation of vaccines. Several hypotheses that might explain the failure of BCG and the strategies designed to address these shortcomings are discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11286732     DOI: 10.1016/s1471-4906(01)01865-8

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  44 in total

1.  Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis.

Authors:  Andras Komocsi; Peter Lamprecht; Elena Csernok; Antje Mueller; Konstanze Holl-Ulrich; Ulrike Seitzer; Frank Moosig; Armin Schnabel; Wolfgang Ludwig Gross
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

2.  Type 1 immunity provides optimal protection against both mucosal and systemic Trypanosoma cruzi challenges.

Authors:  D F Hoft; C S Eickhoff
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

3.  Magnetic resonance imaging of pulmonary lesions in guinea pigs infected with Mycobacterium tuberculosis.

Authors:  Susan L Kraft; Deanna Dailey; Matthew Kovach; Karen L Stasiak; Jamie Bennett; Christine T McFarland; David N McMurray; Angelo A Izzo; Ian M Orme; Randall J Basaraba
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

4.  Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein.

Authors:  Scott M Irwin; Angelo A Izzo; Steven W Dow; Y A W Skeiky; Steven G Reed; Mark R Alderson; Ian M Orme
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

5.  Controversies in BCG immunization.

Authors:  A Parthasarathy
Journal:  Indian J Pediatr       Date:  2003-07       Impact factor: 1.967

Review 6.  Development of new vaccines and drugs for TB: limitations and potential strategic errors.

Authors:  Ian M Orme
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

7.  Specific and randomly derived immunoactive peptide mimotopes of mycobacterial antigens.

Authors:  Archna Sharma; Abhik Saha; Surajit Bhattacharjee; Subrata Majumdar; Sujoy K Das Gupta
Journal:  Clin Vaccine Immunol       Date:  2006-08-17

8.  Immune responses to mycobacterial antigens in the Gambian population: implications for vaccines and immunodiagnostic test design.

Authors:  Johan Vekemans; Martin O C Ota; Jackson Sillah; Katherine Fielding; Mark R Alderson; Yasir A W Skeiky; Wilfried Dalemans; Keith P W J McAdam; Christian Lienhardt; Arnaud Marchant
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  Enhanced protective efficacy against Mycobacterium tuberculosis afforded by BCG prime-DNA boost regimen in an early challenge mouse model is associated with increased splenic interleukin-2-producing CD4 T-cell frequency post-vaccination.

Authors:  Han Kang; Qin Yuan; Hui Ma; Zhi-Dong Hu; De-Ping Han; Kang Wu; Douglas B Lowrie; Xiao-Yong Fan
Journal:  Immunology       Date:  2014-12       Impact factor: 7.397

10.  Screening for potential adjuvants administered by the pulmonary route for tuberculosis vaccines.

Authors:  Chenchen Wang; Pavan Muttil; Dongmei Lu; Adela Ayulia Beltran-Torres; Lucila Garcia-Contreras; Anthony J Hickey
Journal:  AAPS J       Date:  2009-03-10       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.